Shares of Ironwood Pharmaceuticals (IRWD) climbed ~34% on Monday after the company well exceeded Street forecasts with its Q3 2025 financials and hiked its full-year guidance, citing growth prospects for Linzess, a bowel disease therapy it markets with AbbVie (ABBV).
Boston, Massachusetts-based Ironwood (IRWD) recorded $0.24 of non-GAAP earnings per share on $122.1M of revenue, beating the consensus by $0.12 and $46.4M, respectively, compared to $0.02 and $91.6M in the prior-year period.
The company attributed the ~33% YoY growth to rising net profits from U.S. sales of Linzess, which AbbVie (ABBV) recorded as $315M in October, indicating ~40% YoY growth.
“LINZESS delivered a strong third-quarter performance, driven by accelerated double-digit prescription demand growth combined with improved net pricing, which prompted us to raise our full-year 2025 financial guidance,” CEO Tom McCourt remarked.
The company raised its full-year outlook for U.S. Linzess net sales to $860M – $890M and total revenue guidance to $290M – $310M from $800M – $850M and $260M – $290M, respectively.